BPH Energy Limited (ASX:BPH) To Present At The 4th Australian High Content Image Meeting
Perth, Feb 10, 2011 AEST (ABN Newswire) - BPH Energy Limited (
ASX:BPH) is pleased to provide a copy of the presentation that the Principal Researcher Dr. Robin Scaife will present at the 4th Australian High Content Image Meeting in Lorne, Melbourne, today.
High Content Imaging has industrialised the field of microscopy, transforming process like fluorescence microscopy from the single glass slide to a fully automated high-throughput imaging process. Since its inception over ten years ago, high-content imaging and analysis has become a pivotal process in early-stage drug discovery. BPH investee company, Molecular Discovery Systems (MDS), uses high content imaging and analysis to screen for new oncology drugs.
MDS has gained core expertise in high-content screening and high-throughput imaging and analysis. MDS' innovative high content imaging and analysis platform detects and quantifies cellular properties much faster than conventional methods, facilitating in the rapid optimisation and prioritisation of drug leads. MDS has effectively utilised high-content imaging and analysis to identify novel cancer drug candidates.
For the complete BPH Energy Limited announcement including presentation PowerPoint, please refer to the following link:
http://www.abnnewswire.net/media/en/docs/65195-ASX-BPH-528491.pdf
About BPH Energy Limited
BPH Energy Limited (ASX:BPH) is an Australian Securities Exchange listed company developing biomedical research and technologies within Australian Universities and Hospital Institutes.
The company provides early stage funding, project management and commercialisation strategies for a direct collaboration, a spin out company or to secure a license.
BPH provides funding for commercial strategies for proof of concept, research and product development, whilst the institutional partner provides infrastructure and the core scientific expertise.
BPH currently partners with several academic institutions including The Harry Perkins Institute for Medical Research and Swinburne University of Technology (SUT).
| ||
|
